# nature research

Corresponding author(s): Rei Watanabe

Last updated by author(s): Oct 27, 2020

# **Reporting Summary**

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.

#### Statistics

Fora	all st	atistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Cor	nfirmed
	×	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	X	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	×	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	×	A description of all covariates tested
	×	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	×	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	×	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i> ) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
X		For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
X		For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
X		Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated
		Our web collection on statistics for biologists contains articles on many of the points above.
	_	

#### Software and code

Policy information about availability of computer code Data collection No software was used. Statistical analyses were performed using Prism8.4.3 (GraphPad Software, CA, USA).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

### Data

Data analysis

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

The authors declare that most data supporting the findings of this study are available within the paper and its supplementary information files. Additional raw data generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

# Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

× Life sciences

Behavioural & social sciences

Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>

# Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	Sample-size calculation was not performed. In our previous research on human samples, 3-6 samples per aging groups or antigen stimulation groups led to reproducible statistical differences (Watanabe et al, Sci Transl Med 2015) and we aimed for these sample sizes for each experiment. We reached the similar findings from different races by different experimental methods, and we hope it will suggest the sufficiency of the sample sizes.
Data exclusions	No data were excluded from the analyses.
Replication	We verified the reproducibility of our findings by analyzing the samples from two different countries by independent experimental methods.
Randomization	The randomization procedure is not applicable in our observational study.
Blinding	The researchers who did the experiments were blinded for the age information.

# Behavioural & social sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description	Briefly describe the study type including whether data are quantitative, qualitative, or mixed-methods (e.g. qualitative cross-sectional, quantitative experimental, mixed-methods case study).
Research sample	State the research sample (e.g. Harvard university undergraduates, villagers in rural India) and provide relevant demographic information (e.g. age, sex) and indicate whether the sample is representative. Provide a rationale for the study sample chosen. For studies involving existing datasets, please describe the dataset and source.
Sampling strategy	Describe the sampling procedure (e.g. random, snowball, stratified, convenience). Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient. For qualitative data, please indicate whether data saturation was considered, and what criteria were used to decide that no further sampling was needed.
Data collection	Provide details about the data collection procedure, including the instruments or devices used to record the data (e.g. pen and paper, computer, eye tracker, video or audio equipment) whether anyone was present besides the participant(s) and the researcher, and whether the researcher was blind to experimental condition and/or the study hypothesis during data collection.
Timing	Indicate the start and stop dates of data collection. If there is a gap between collection periods, state the dates for each sample cohort.
Data exclusions	If no data were excluded from the analyses, state so OR if data were excluded, provide the exact number of exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.
Non-participation	State how many participants dropped out/declined participation and the reason(s) given OR provide response rate OR state that no participants dropped out/declined participation.
Randomization	If participants were not allocated into experimental groups, state so OR describe how participants were allocated to groups, and if allocation was not random, describe how covariates were controlled.

# Ecological, evolutionary & environmental sciences study design

All studies must disclose on these points even when the disclosure is negative.

Study description

Briefly describe the study. For quantitative data include treatment factors and interactions, design structure (e.g. factorial, nested, hierarchical), nature and number of experimental units and replicates.

Research sample	Describe the research sample (e.g. a group of tagged Passer domesticus, all Stenocereus thurberi within Organ Pipe Cactus National Monument), and provide a rationale for the sample choice. When relevant, describe the organism taxa, source, sex, age range and any manipulations. State what population the sample is meant to represent when applicable. For studies involving existing datasets, describe the data and its source.
Sampling strategy	Note the sampling procedure. Describe the statistical methods that were used to predetermine sample size OR if no sample-size calculation was performed, describe how sample sizes were chosen and provide a rationale for why these sample sizes are sufficient.
Data collection	Describe the data collection procedure, including who recorded the data and how.
Timing and spatial scale	Indicate the start and stop dates of data collection, noting the frequency and periodicity of sampling and providing a rationale for these choices. If there is a gap between collection periods, state the dates for each sample cohort. Specify the spatial scale from which the data are taken
Data exclusions	If no data were excluded from the analyses, state so OR if data were excluded, describe the exclusions and the rationale behind them, indicating whether exclusion criteria were pre-established.
Reproducibility	Describe the measures taken to verify the reproducibility of experimental findings. For each experiment, note whether any attempts to repeat the experiment failed OR state that all attempts to repeat the experiment were successful.
Randomization	Describe how samples/organisms/participants were allocated into groups. If allocation was not random, describe how covariates were controlled. If this is not relevant to your study, explain why.
Blinding	Describe the extent of blinding used during data acquisition and analysis. If blinding was not possible, describe why OR explain why blinding was not relevant to your study.
Did the study involve fiel	d work? Yes No

# Field work, collection and transport

Field conditions	Describe the study conditions for field work, providing relevant parameters (e.g. temperature, rainfall).
Location	State the location of the sampling or experiment, providing relevant parameters (e.g. latitude and longitude, elevation, water depth).
Access & import/export	Describe the efforts you have made to access habitats and to collect and import/export your samples in a responsible manner and in compliance with local, national and international laws, noting any permits that were obtained (give the name of the issuing authority, the date of issue, and any identifying information).
Disturbance	Describe any disturbance caused by the study and how it was minimized.

# Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

Ma	terial	s &	experimenta	systems

**X** Dual use research of concern

Methods	

n/a	Involved in the study	n/a   Involved in the study
	X Antibodies	ChIP-seq
×	Eukaryotic cell lines	Flow cytometry
×	Palaeontology and archaeology	🗶 🗌 MRI-based neuroimaging
×	Animals and other organisms	
	X Human research participants	
×	Clinical data	

### Antibodies

Antibodies used	Described in the supplementary Table.
Validation	All the antibodies were commercially available and the validation of each antibody was confirmed by the manufacturers' websites.

# Eukaryotic cell lines

Policy information about <u>cell lines</u>		
Cell line source(s)	State the source of each cell line used.	
Authentication	Describe the authentication procedures for each cell line used OR declare that none of the cell lines used were authenticated.	
Mycoplasma contamination	Confirm that all cell lines tested negative for mycoplasma contamination OR describe the results of the testing for mycoplasma contamination OR declare that the cell lines were not tested for mycoplasma contamination.	
Commonly misidentified lines (See <u>ICLAC</u> register)	Name any commonly misidentified cell lines used in the study and provide a rationale for their use.	

### Palaeontology and Archaeology

Specimen provenance	Provide provenance information for specimens and describe permits that were obtained for the work (including the name of the issuing authority, the date of issue, and any identifying information).
Specimen deposition	Indicate where the specimens have been deposited to permit free access by other researchers.
Dating methods	If new dates are provided, describe how they were obtained (e.g. collection, storage, sample pretreatment and measurement), where they were obtained (i.e. lab name), the calibration program and the protocol for quality assurance OR state that no new dates are provided.
Tick this box to conf	rm that the raw and calibrated dates are available in the paper or in Supplementary Information.
Ethics oversight	Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

# Animals and other organisms

#### Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

Laboratory animals	(For laboratory animals, report species, strain, sex and age OR state that the study did not involve laboratory animals.
Wild animals	Provide details on animals observed in or captured in the field; report species, sex and age where possible. Describe how animals were caught and transported and what happened to captive animals after the study (if killed, explain why and describe method; if released, say where and when) OR state that the study did not involve wild animals.
Field-collected samples	For laboratory work with field-collected samples, describe all relevant parameters such as housing, maintenance, temperature, photoperiod and end-of-experiment protocol OR state that the study did not involve samples collected from the field.
Ethics oversight	Identify the organization(s) that approved or provided guidance on the study protocol, OR state that no ethical approval or guidance was required and explain why not.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Human research participants

Policy information about studie	s involving human research participants
Population characteristics	Described in the Supplementary Table.
Recruitment	The subjects were recruited only when the written informed consent was obtained. Researchers doing experiments were not involved in the recruitment process.
Ethics oversight	The institutional review board of the ethics committee of University of Tsukuba Hospital (approval number H28-001) and Karolinska Institutet, regional ethics committee of Stockholm (reference no. 2012/50-31/2)

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Clinical data

Policy information about clinical studies All manuscripts should comply with the ICMJEguidelines for publication of clinical research and a completed CONSORT checklist must be included with all submissions.	
Clinical trial registration	Provide the trial registration number from ClinicalTrials.gov or an equivalent agency.
Study protocol	Note where the full trial protocol can be accessed OR if not available, explain why.

Outcomes

Describe the settings and locales of data collection, noting the time periods of recruitment and data collection.

Describe how you pre-defined primary and secondary outcome measures and how you assessed these measures.

#### Dual use research of concern

#### Policy information about dual use research of concern

#### Hazards

Could the accidental, deliberate or reckless misuse of agents or technologies generated in the work, or the application of information presented in the manuscript, pose a threat to:

 No
 Yes

 Public health
 Public health

 National security
 Crops and/or livestock

 Ecosystems
 Any other significant area

#### Experiments of concern

Does the work involve any of these experiments of concern:

No	Yes
	Demonstrate how to render a vaccine ineffective
	Confer resistance to therapeutically useful antibiotics or antiviral agents
	Enhance the virulence of a pathogen or render a nonpathogen virulent
	I Increase transmissibility of a pathogen
	Alter the host range of a pathogen
	Enable evasion of diagnostic/detection modalities
	Enable the weaponization of a biological agent or toxin
	Any other potentially harmful combination of experiments and agents

### ChIP-seq

#### Data deposition

Confirm that both raw and final processed data have been deposited in a public database such as GEO.

Confirm that you have deposited or provided access to graph files (e.g. BED files) for the called peaks.

Data access links May remain private before publication.	For "Initial submission" or "Revised version" documents, provide reviewer access links. For your "Final submission" document, provide a link to the deposited data.
Files in database submission	Provide a list of all files available in the database submission.
Genome browser session (e.g. <u>UCSC</u> )	Provide a link to an anonymized genome browser session for "Initial submission" and "Revised version" documents only, to enable peer review. Write "no longer applicable" for "Final submission" documents.

#### Methodology

Replicates	Describe the experimental replicates, specifying number, type and replicate agreement.
Sequencing depth	Describe the sequencing depth for each experiment, providing the total number of reads, uniquely mapped reads, length of reads and whether they were paired- or single-end.
Antibodies	Describe the antibodies used for the ChIP-seq experiments; as applicable, provide supplier name, catalog number, clone name, and lot number.
Peak calling parameters	Specify the command line program and parameters used for read mapping and peak calling, including the ChIP, control and index files used.
Data quality	Describe the methods used to ensure data quality in full detail, including how many peaks are at FDR 5% and above 5-fold enrichment.

Describe the software used to collect and analyze the ChIP-seq data. For custom code that has been deposited into a community repository, provide accession details.

### Flow Cytometry

#### Plots

Confirm that:

The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).

The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).

All plots are contour plots with outliers or pseudocolor plots.

**X** A numerical value for number of cells or percentage (with statistics) is provided.

#### Methodology

Sample preparation	Described in the Methods.
Instrument	Gallios Cytofluorometer, CyAn ADP analyzer (Beckman Coulter, CA, USA) or an LSR-II (BD Biosciences),
Software	Kaluza analysis software (Beckman Coulter) or FlowJo (Tree Star, OR, USA)
Cell population abundance	There were not sorted populations in this study and T cell isolation methods were described in the Method section.
Gating strategy	Described in the Supplementary Figure 3.

**x** Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.

## Magnetic resonance imaging

#### Experimental design

Design type	Indicate task or resting state; event-related or block design.	
Design specifications	Specify the number of blocks, trials or experimental units per session and/or subject, and specify the length of each trial or block (if trials are blocked) and interval between trials.	
Behavioral performance measure	es State number and/or type of variables recorded (e.g. correct button press, response time) and what statistics were used to establish that the subjects were performing the task as expected (e.g. mean, range, and/or standard deviation across subjects).	
Acquisition		
Imaging type(s)	Specify: functional, structural, diffusion, perfusion.	
Field strength	Specify in Tesla	
Sequence & imaging parameters	Specify the pulse sequence type (gradient echo, spin echo, etc.), imaging type (EPI, spiral, etc.), field of view, matrix size, slice thickness, orientation and TE/TR/flip angle.	
Area of acquisition	State whether a whole brain scan was used OR define the area of acquisition, describing how the region was determined.	
Diffusion MRI Used	Not used	
	—	
Preprocessing		
Preprocessing Preprocessing software	Provide detail on software version and revision number and on specific parameters (model/functions, brain extraction, segmentation, smoothing kernel size, etc.).	
Preprocessing software	segmentation, smoothing kernel size, etc.). If data were normalized/standardized, describe the approach(es): specify linear or non-linear and define image types used for	

Define your software and/or method and criteria for volume censoring, and state the extent of such censoring.

### Statistical modeling & inference

Model type and settings	Specify type (mass univariate, multivariate, RSA, predictive, etc.) and describe essential details of the model at the first and second levels (e.g. fixed, random or mixed effects; drift or auto-correlation).
Effect(s) tested	Define precise effect in terms of the task or stimulus conditions instead of psychological concepts and indicate whether ANOVA or factorial designs were used.
Specify type of analysis: 🗌 W	/hole brain 🗌 ROI-based 🔲 Both
Statistic type for inference (See <u>Eklund et al. 2016</u> )	Specify voxel-wise or cluster-wise and report all relevant parameters for cluster-wise methods.
Correction	Describe the type of correction and how it is obtained for multiple comparisons (e.g. FWE, FDR, permutation or Monte Carlo).
Models & analysis	
n/a Involved in the study	
Functional and/or effectiv	e connectivity
Graph analysis	

Multivariate modeling or predictive analysis

Functional and/or effective connectivity	Report the measures of dependence used and the model details (e.g. Pearson correlation, partial correlation, mutual information).
Graph analysis	Report the dependent variable and connectivity measure, specifying weighted graph or binarized graph, subject- or group-level, and the global and/or node summaries used (e.g. clustering coefficient, efficiency, etc.).
Multivariate modeling and predictive analysis	Specify independent variables, features extraction and dimension reduction, model, training and evaluation metrics